摘要
目的比较氟康唑与伏立康唑治疗肺部真菌感染的临床疗效和安全性。方法选取已确诊的肺部真菌感染67例患者随机分为2组,分别给予氟康唑和伏立康唑治疗,分析2组患者的临床疗效和不良反应情况。结果伏立康唑组在缓解发热、咳嗽等临床症状方面明显优于氟康唑组(P<0.05);伏立康唑组的治疗有效率为84.38%,明显高于氟康唑组的治疗有效率62.86%(P<0.05);2组患者在低血钾、胃肠道反应、转氨酶升高等不良反应方面无明显差异(P>0.05)。结论氟康唑和伏立康唑都是治疗肺部真菌感染的有效药物,二者安全性相仿,但伏立康唑的疗效优于氟康唑。
Objective To observe and compare the effectiveness and safety of fluconazole and voriconazole in the treatment of severe pulmonary fungal infection .Methods 67 patients with severe fungal infections in intensive care unit of our hospital were randomly divided into 2 groups ,fluconazole group and voriconazole group .Therapeutic efficacy and adverse drug reactions were observed in the 2 groups .Results The symptom of voriconazole group was better than that of fluconazole group （P〈0 .05） .For fluconazole group and voriconazole group ,the effective rates were 62 .86% and 84 .38% ,respectively ,and there was statistical significance （P〈0.05） .But there was no statistical significance in the incidence of ADR between the 2 groups（P〉0 .05） .Conclusion The effi-cacy of voriconazole is superior to fluconazole in the treatment of severe pulmonary fungal infection ,but the safety is same .
出处
《西北药学杂志》
CAS
2014年第3期283-285,共3页
Northwest Pharmaceutical Journal
关键词
氟康唑
伏立康唑
肺部真菌感染
fluconazole
voriconazole
pulmonary fungal infection
